文献速递肝病

平台试验能否克服非酒精性脂肪性肝炎传统临床试验的主要缺陷?利弊分析

Platform trials to overcome major shortcomings of traditional clinical trials in non-alcoholic steatohepatitis? Pros and cons.
PubMed 文献 · J Hepatol · 2022-10-08

非酒精性脂肪性肝炎(NASH)患病率高但尚无获批药物,传统临床试验的方法学与操作特征可能阻碍药物研发。本文分析平台试验作为传统试验补充或替代方案的利弊,平台试验采用主方案与共享对照组,通过贝叶斯期中分析实现药物早期退出和适应性随机化。

要点

  • NASH患病率高且可进展为肝硬化和肝细胞癌,目前尚无获批药物。
  • 传统NASH临床试验的方法学与操作特征可能阻碍药物研发。
  • 平台试验采用主方案与共享对照组,通过贝叶斯期中分析实现早期退出和适应性随机化。

核心结论

  • 平台试验可为患者、制药公司和临床医生提供一种替代方案,以加速NASH药物治疗的获批。
  • 平台试验可能是传统临床试验有吸引力的补充或替代。

研究设计与样本

  • 本文为论述性文章,分析平台试验在NASH药物研发中的利弊。

主要发现

  • 非酒精性脂肪性肝病影响25%的人群,NASH可导致肝硬化和肝细胞癌等严重并发症。
  • NASH药物研发管线活跃,但大多数资产未进入III期试验,进入III期者常未能达到监管机构批准所需的终点。
  • 平台试验使用主方案,可同时或序贯评估多种研究用药品,并共享一个对照组。
  • 平台试验通过贝叶斯期中分析,基于成功或无效允许药物早期退出,并通过适应性随机化提高参与者接受活性化合物的机会。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Non-alcoholic fatty liver disease is a condition that affects 25% of the population. Non-alcoholic steatohepatitis (NASH) is a progressive form of the disease that can lead to severe complications such as cirrhosis and hepatocellular carcinoma. Despite its high prevalence, no drugs are currently approved for the treatment of NASH. The drug development pipeline in NASH is very active, yet most assets do not progress to phase III trials and those that do reach phase III often fail to achieve the endpoints necessary for approval by regulatory agencies. Amongst other reasons, the methodological and operational features of traditional clinical trials in NASH might impede optimal drug development. In this regard, platform trials might be an attractive complement or alternative to conventional clinical trials. Platform trials use a master protocol which enables evaluation of multiple investigational medicinal products concurrently or sequentially with a single, shared control arm. Through Bayesian interim analyses, these trials allow for early exit of drugs from the trial based on success or futility, while providing participants better chances of receiving active compounds through adaptive randomisation. Overall, platform trials represent an alternative for patients, pharmaceutical companies, and clinicians in the quest to accelerate the approval of pharmacologic treatments for NASH.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Pericàs JM, Tacke F, Anstee QM, et al. Platform trials to overcome major shortcomings of traditional clinical trials in non-alcoholic steatohepatitis? Pros and cons. J Hepatol. 2022. PMID: 36216134. doi:10.1016/j.jhep.2022.09.021

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。